What is Vycor Med Inc's earnings per share (EPS)?

Vycor Med Inc (VYCO) reported diluted earnings per share of $-0.01 for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Vycor Med Inc Financials

VYCO

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Vycor Med Inc (VYCO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VYCO FY2025 2026-05-15

High gross margins are largely absorbed by selling overhead, leaving VYCO reliant on liabilities instead of durable cash generation.

FY2025 produced positive operating income of $34K after FY2024's slight operating loss, yet operating cash flow slipped to -$13K. With current assets at only $563K against $4.8M of current liabilities, small working-capital demands can wipe out progress at the income-statement level.

Gross margin stayed unusually high at 83.8% in FY2025, but SG&A still ran at $1.5M, nearly consuming the gross profit pool. The brief operating-profit turns in FY2023 and FY2025, followed by continued net losses, suggest the core selling engine can occasionally cover overhead but not all costs that sit below operating income.

The balance sheet remains heavily liability-funded: total liabilities reached $4.9M while total assets fell to $830K. Because no long-term debt is reported, the strain appears concentrated in short-term obligations rather than spread over many years, which helps explain why cash generation has been fragile even when reported operating results improve.

Financial Health Signals

Financial Profile 35/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Vycor Med Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Vycor Med Inc has an operating margin of 1.8%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 25/100, suggesting thin profitability after operating expenses. This is up from -0.6% the prior year.

Growth

Vycor Med Inc's revenue surged 17.2% year-over-year to $1.9M, reflecting rapid business expansion. This strong growth earns a score of 55/100.

Leverage

100

Vycor Med Inc carries a low D/E ratio of -1.20, meaning only $-1.20 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Vycor Med Inc's current ratio of 0.12 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

While Vycor Med Inc generated -$13K in operating cash flow, capex of $5K consumed most of it, leaving -$19K in free cash flow. This results in a low score of 27/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Neutral

4/9

Vycor Med Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.19x

For every $1 of reported earnings, Vycor Med Inc generates $0.19 in operating cash flow (-$13K OCF vs -$72K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.9M

YoY+17.2%

5Y CAGR+10.3%

10Y CAGR+5.0%

Vycor Med Inc generated $1.9M in revenue in fiscal year 2025. This represents an increase of 17.2% from the prior year.

EBITDA

$93K

YoY+85.4%

Vycor Med Inc's EBITDA was $93K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 85.4% from the prior year.

Net Income

-$72K

YoY+32.4%

Vycor Med Inc reported -$72K in net income in fiscal year 2025. This represents an increase of 32.4% from the prior year.

EPS (Diluted)

$-0.01

YoY+0.0%

Vycor Med Inc earned $-0.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$19K

YoY-134.1%

Vycor Med Inc generated -$19K in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 134.1% from the prior year.

Cash & Debt

$87K

YoY-17.7%

5Y CAGR+13.6%

10Y CAGR-12.9%

Vycor Med Inc held $87K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

33M

YoY+0.0%

5Y CAGR+4.0%

10Y CAGR+11.8%

Vycor Med Inc had 33M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

83.8%

YoY-5.7pp

5Y CAGR-4.6pp

10Y CAGR-1.8pp

Vycor Med Inc's gross margin was 83.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 5.7 percentage points from the prior year.

Operating Margin

1.8%

YoY+2.4pp

5Y CAGR+65.5pp

10Y CAGR+176.7pp

Vycor Med Inc's operating margin was 1.8% in fiscal year 2025, reflecting core business profitability. This is up 2.4 percentage points from the prior year.

Net Margin

-3.9%

YoY+2.9pp

5Y CAGR+68.1pp

10Y CAGR+179.0pp

Vycor Med Inc's net profit margin was -3.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.9 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$10K

YoY-35.0%

10Y CAGR-17.9%

Vycor Med Inc invested $10K in research and development in fiscal year 2025. This represents a decrease of 35.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5K

YoY-2.6%

5Y CAGR-39.0%

10Y CAGR-30.9%

Vycor Med Inc invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 2.6% from the prior year.

VYCO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.9M+17.2%	$1.6M+8.8%	$1.5M+19.4%	$1.2M-12.2%	$1.4M+22.0%	$1.1M
Cost of Revenue	$302K+81.2%	$167K+15.1%	$145K+3.1%	$141K+4.4%	$135K+1.7%	$132K
Gross Profit	$1.6M+9.7%	$1.4M+8.1%	$1.3M+21.6%	$1.1M-14.0%	$1.3M+24.6%	$1.0M
R&D Expenses	$10K-35.0%	$15K-32.1%	$23K	N/A	$15K	$0
SG&A Expenses	$1.5M+7.4%	$1.4M+13.5%	$1.2M-10.2%	$1.3M-17.5%	$1.6M-4.0%	$1.7M
Operating Income	$34K+470.7%	-$9K-122.8%	$40K+113.1%	-$307K+29.7%	-$436K+40.1%	-$727K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$72K+32.4%	-$107K-53.8%	-$70K+82.8%	-$405K+7.1%	-$436K+47.0%	-$822K
EPS (Diluted)	$-0.010.0%	$-0.010.0%	$-0.01+50.0%	$-0.02	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$459K+10.0%	$417K-18.9%	$514K+3.5%	$496K+13.7%	$436K-4.1%	$455K+16.5%	$391K-3.8%	$406K
Cost of Revenue	$83K+2.3%	$82K+31.8%	$62K-23.7%	$81K+4.2%	$78K+34.6%	$58K+57.2%	$37K+4.6%	$35K
Gross Profit	$375K+11.9%	$335K-25.8%	$452K+8.8%	$415K+15.8%	$359K-9.8%	$397K+12.2%	$354K-4.6%	$371K
R&D Expenses	N/A	N/A	N/A	$4K-27.1%	$6K	N/A	$6K+183.9%	$2K
SG&A Expenses	$315K-11.7%	$357K-11.8%	$405K+17.4%	$345K-1.6%	$351K-1.6%	$357K-3.1%	$368K+8.9%	$338K
Operating Income	$46K+225.4%	-$37K-213.8%	$32K-37.3%	$51K+499.4%	-$13K-166.2%	$19K+155.1%	-$35K-317.2%	$16K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$20K+132.1%	-$63K-1370.0%	$5K-79.3%	$24K+161.9%	-$39K-472.4%	-$7K+88.7%	-$60K-495.9%	-$10K
EPS (Diluted)	$0.00	N/A	$0.00	$0.00+100.0%	$-0.01	N/A	$-0.01	$0.00

VYCO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$830K-16.8%	$998K+0.6%	$992K+15.4%	$860K-8.0%	$935K-5.2%	$987K
Current Assets	$563K-9.1%	$620K+6.1%	$584K+12.8%	$518K+6.2%	$487K+5.1%	$464K
Cash & Equivalents	$87K-17.7%	$106K+84.4%	$57K+54.7%	$37K-59.3%	$91K+97.7%	$46K
Inventory	$159K+9.0%	$146K-37.6%	$234K-5.9%	$249K+19.9%	$208K+14.6%	$181K
Accounts Receivable	$219K-10.8%	$245K+14.0%	$215K+37.8%	$156K+23.9%	$126K-20.8%	$159K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.9M+4.9%	$4.7M+8.6%	$4.3M+13.6%	$3.8M+360.4%	-$1.5M-149.2%	$3.0M
Current Liabilities	$4.8M+6.3%	$4.5M+10.4%	$4.1M+11.5%	$3.7M+16.0%	$3.1M+14.9%	$2.7M
Long-Term Debt	N/A	N/A	N/A	N/A	$150K0.0%	$150K
Total Equity	-$4.1M-10.8%	-$3.7M-11.0%	-$3.3M-13.1%	-$2.9M-222.8%	$2.4M+220.9%	-$2.0M
Retained Earnings	-$33.6M-1.2%	-$33.3M-1.3%	-$32.8M-1.2%	-$32.4M-2.3%	-$31.7M-2.5%	-$30.9M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$854K+2.8%	$830K-11.8%	$941K+7.1%	$879K-6.6%	$941K-5.7%	$998K-7.1%	$1.1M+7.8%	$997K
Current Assets	$651K+15.6%	$563K-15.0%	$663K+19.5%	$554K-7.7%	$601K-3.1%	$620K-16.7%	$743K+15.5%	$643K
Cash & Equivalents	$174K+99.6%	$87K+35.4%	$64K-35.6%	$100K+63.3%	$61K-42.2%	$106K-33.0%	$158K+32.1%	$119K
Inventory	$182K+14.3%	$159K-4.9%	$167K+7.3%	$156K-11.5%	$176K+20.7%	$146K-22.1%	$188K-14.1%	$218K
Accounts Receivable	$194K-11.4%	$219K-32.9%	$326K+60.9%	$203K-11.7%	$229K-6.5%	$245K+2.7%	$239K-5.6%	$253K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.1M+3.4%	$4.9M-1.0%	$5.0M+4.6%	$4.7M-1.8%	$4.8M+3.1%	$4.7M-1.5%	$4.8M+5.1%	$4.5M
Current Liabilities	$4.9M+3.5%	$4.8M-0.7%	$4.8M+5.1%	$4.6M-1.5%	$4.7M+3.5%	$4.5M-1.2%	$4.6M+5.7%	$4.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$4.2M-3.5%	-$4.1M-1.6%	-$4.0M-4.1%	-$3.9M+0.6%	-$3.9M-5.4%	-$3.7M-0.2%	-$3.7M-4.4%	-$3.5M
Retained Earnings	-$33.8M-0.4%	-$33.6M-0.2%	-$33.6M-0.5%	-$33.4M+0.1%	-$33.5M-0.6%	-$33.3M0.0%	-$33.2M-0.7%	-$33.0M

VYCO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$13K-122.4%	$60K+104.2%	$29K+113.6%	-$217K-1115.6%	$21K+108.6%	-$249K
Capital Expenditures	$5K-2.6%	$5K-42.8%	$9K+237.6%	$3K-92.8%	$38K-38.2%	$62K
Free Cash Flow	-$19K-134.1%	$55K+173.1%	$20K+109.1%	-$220K-1192.5%	-$17K+94.5%	-$311K
Investing Cash Flow	-$4K-4.4%	-$4K+55.3%	-$9K-237.6%	-$3K+92.8%	-$38K+26.9%	-$52K
Financing Cash Flow	-$812+89.3%	-$8K-3680.1%	$211-99.9%	$166K+167.8%	$62K-78.4%	$287K
Dividends Paid	N/A	N/A	$324K0.0%	$324K	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$99K+153.4%	$39K+154.2%	-$72K-255.3%	$47K+273.3%	-$27K+29.7%	-$38K-465.6%	$10K-87.8%	$86K
Capital Expenditures	N/A	$2K+160400.0%	$1	N/A	N/A	-$2	N/A	N/A
Free Cash Flow	N/A	$38K+152.0%	-$72K	N/A	N/A	-$38K	N/A	N/A
Investing Cash Flow	$2K+233.3%	-$2K	$0	N/A	N/A	$170+103.4%	-$5K	$0
Financing Cash Flow	-$15K-0.2%	-$15K-140.2%	$37K+810.0%	-$5K+70.6%	-$18K-27.5%	-$14K-142.2%	$33K+410.5%	-$11K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VYCO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	83.8%-5.7pp	89.5%-0.6pp	90.1%+1.6pp	88.5%-1.8pp	90.3%+1.9pp	88.4%
Operating Margin	1.8%+2.4pp	-0.6%-3.3pp	2.8%+27.8pp	-25.1%+6.2pp	-31.3%+32.4pp	-63.7%
Net Margin	-3.9%+2.9pp	-6.8%-2.0pp	-4.8%+28.3pp	-33.1%-1.8pp	-31.3%+40.7pp	-72.0%
Return on Equity	N/A	N/A	N/A	N/A	-18.2%	N/A
Return on Assets	-8.7%+2.0pp	-10.7%-3.7pp	-7.0%+40.1pp	-47.1%-0.5pp	-46.6%+36.8pp	-83.4%
Current Ratio	0.12-0.0	0.140.0	0.140.0	0.14-0.0	0.15-0.0	0.17
Debt-to-Equity	-1.20+0.1	-1.27+0.0	-1.300.0	-1.29-1.4	0.06+0.1	-0.08
FCF Margin	-1.0%-4.4pp	3.4%+2.1pp	1.4%+19.3pp	-18.0%-16.8pp	-1.2%+26.0pp	-27.2%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	81.8%+1.4pp	80.5%-7.5pp	88.0%+4.3pp	83.7%+1.5pp	82.2%-5.1pp	87.3%-3.3pp	90.6%-0.8pp	91.3%
Operating Margin	10.0%+18.8pp	-8.8%-15.0pp	6.2%-4.1pp	10.3%+13.2pp	-2.9%-7.2pp	4.3%+13.2pp	-9.0%-13.0pp	4.0%
Net Margin	4.4%+19.4pp	-15.0%-16.0pp	1.0%-3.9pp	4.8%+13.7pp	-8.8%-7.4pp	-1.5%+13.8pp	-15.3%-12.8pp	-2.5%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	2.4%+9.9pp	-7.5%-8.1pp	0.5%-2.2pp	2.7%+6.8pp	-4.1%-3.4pp	-0.7%+4.9pp	-5.6%-4.6pp	-1.0%
Current Ratio	0.13+0.0	0.12-0.0	0.14+0.0	0.120.0	0.130.0	0.14-0.0	0.16+0.0	0.15
Debt-to-Equity	-1.200.0	-1.20+0.0	-1.230.0	-1.23+0.0	-1.24+0.0	-1.27+0.0	-1.290.0	-1.28
FCF Margin	N/A	9.0%+23.1pp	-14.1%	N/A	N/A	-8.4%	N/A	N/A

Note: Shareholder equity is negative (-$4.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.12), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is Vycor Med Inc's annual revenue?

Vycor Med Inc (VYCO) reported $1.9M in total revenue for fiscal year 2025. This represents a 17.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Vycor Med Inc's revenue growing?

Vycor Med Inc (VYCO) revenue grew by 17.2% year-over-year, from $1.6M to $1.9M in fiscal year 2025.

Is Vycor Med Inc profitable?

No, Vycor Med Inc (VYCO) reported a net income of -$72K in fiscal year 2025, with a net profit margin of -3.9%.

What is Vycor Med Inc's EBITDA?

Vycor Med Inc (VYCO) had EBITDA of $93K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Vycor Med Inc's gross margin?

Vycor Med Inc (VYCO) had a gross margin of 83.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Vycor Med Inc's operating margin?

Vycor Med Inc (VYCO) had an operating margin of 1.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Vycor Med Inc's net profit margin?

Vycor Med Inc (VYCO) had a net profit margin of -3.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Vycor Med Inc's free cash flow?

Vycor Med Inc (VYCO) generated -$19K in free cash flow during fiscal year 2025. This represents a -134.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Vycor Med Inc's operating cash flow?

Vycor Med Inc (VYCO) generated -$13K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Vycor Med Inc's total assets?

Vycor Med Inc (VYCO) had $830K in total assets as of fiscal year 2025, including both current and long-term assets.

What are Vycor Med Inc's capital expenditures?

Vycor Med Inc (VYCO) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Vycor Med Inc spend on research and development?

Vycor Med Inc (VYCO) invested $10K in research and development during fiscal year 2025.

How many shares does Vycor Med Inc have outstanding?

Vycor Med Inc (VYCO) had 33M shares outstanding as of fiscal year 2025.

What is Vycor Med Inc's current ratio?

Vycor Med Inc (VYCO) had a current ratio of 0.12 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Vycor Med Inc's debt-to-equity ratio?

Vycor Med Inc (VYCO) had a debt-to-equity ratio of -1.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Vycor Med Inc's return on assets (ROA)?

Vycor Med Inc (VYCO) had a return on assets of -8.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Vycor Med Inc's cash runway?

Based on fiscal year 2025 data, Vycor Med Inc (VYCO) had $87K in cash against an annual operating cash burn of $13K. This gives an estimated cash runway of approximately 77 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Vycor Med Inc's debt-to-equity ratio negative or unusual?

Vycor Med Inc (VYCO) has negative shareholder equity of -$4.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Vycor Med Inc's Piotroski F-Score?

Vycor Med Inc (VYCO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Vycor Med Inc's earnings high quality?

Vycor Med Inc (VYCO) has an earnings quality ratio of 0.19x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Vycor Med Inc?

Vycor Med Inc (VYCO) scores 35 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.